Skip to main content
Addgene

Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.

Xie Y, Wang Y, Xu Z, Lu Y, Song D, Gao L, Yu D, Li B, Chen G, Zhang H, Feng Q, Zhang Y, Hu K, Huang C, Peng Y, Wu X, Mao Z, Shao J, Zhu W, Shi J
J Biomed Sci. 2022 May 12;29(1):32. doi: 10.1186/s12929-022-00813-2. (Link opens in a new window) PubMed (Link opens in a new window) Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.

Antibodies from Article